Investing in our future
Investing in our future
Investing in our future
Who are we looking for?
As a fund, we are seeking investors to join our mission: to invest in the future of healthcare, inspire change, and ignite the world, all while seeking to add value for our investors and portfolio companies that benefit humanity.
We partner with those who align with our goals and values within family offices, institutions, and funds of funds. We are interested in building our portfolio with impact-minded investors who aim to transform systems for change.
Does it sound like you?
Does it sound like you?
Why Invest Now?
Potential for High Returns
Early-stage biotech companies are often ground zero for groundbreaking scientific innovations and novel drug candidates. Investing in the companies at their infancy provides an opportunity to capitalize on their potential success and achieve significant financial returns.
Personalized Treatment
Precision medicine enables healthcare providers to select the most effective treatments based on a patient’s unique genetic, molecular, and clinical profile. This can lead to improved outcomes and reduced adverse effects compared to a one-size-fits-all approach.
Early Detection and Prevention
Genetic testing and advanced diagnostic technologies allow for the early detection of diseases and the identification of individuals at higher risk. This enables proactive interventions, such as lifestyle modifications or preventive treatments, to reduce the likelihood of disease development or progression.
Advancements in Research
Precision medicine generates vast amounts of data that can be used to better understand disease mechanisms, identify new therapeutic targets, and improve clinical trial design. This accelerates the development of novel treatments and enhances our understanding of complex diseases.
Preventive Medicine
Precision medicine shifts the focus from reactive healthcare to proactive disease prevention and early intervention. By identifying individuals at risk of developing certain conditions, interventions can be implemented to prevent or delay disease onset, ultimately improving overall population health.
Diversification Benefits
Including early-stage biotech investments in a diversified portfolio can offer investors exposure to high-growth assets that may not be correlated with traditional market performance. This diversification helps mitigate overall portfolio risk and enhances long-term returns.
Valuation Upside
Early-stage biotech companies are typically valued based on their
pipeline potential and scientific progress. Positive milestones such as successful clinical trial results or regulatory approvals can lead to significant increases in the company’s valuation, offering investors the potential for substantial upside.
Innovation and Disruption
Biotechnology is a dynamic and rapidly evolving field known for its potential to disrupt traditional standards of care. By investing in early stage biotech, investors can be at the forefront of innovation, supporting the development of novel treatments and therapies that have the potential to revolutionize healthcare.
Targeted Therapies
By understanding the genetic mutations driving diseases, precision medicine facilitates the development of targeted therapies that specifically address the underlying causes. This can result in more effective treatments with fewer side effects.
Reduced Healthcare Costs
While upfront costs for genetic testing and personalized treatments may be higher, precision medicine has the potential to reduce overall healthcare costs by avoiding ineffective treatments, minimizing hospitalizations, and preventing the progression of diseases to more advanced stages.
Health Equity
By considering individual variations in genetics, environment, and lifestyle, precision medicine has the potential to address health disparities and ensure equitable access to healthcare services and treatments for diverse populations.
Patient Empowerment
Precision medicine empowers patients by providing them with personalized information about their health risks, treatment options, and prognosis. This enables informed decision-making and active participation in their healthcare journey.
Impactful Solutions to Medical Challenges
Investing in early-stage biotech allows investors to support the development of potentially life-changing therapies for patients suffering from serious diseases and conditions. The opportunity to contribute to meaningful advancements in healthcare can be a motivating factor for investors seeking both financial and social impact.
Scientific Expertise
Building a biotech therapeutics company begins with assembling a team of experienced scientists, researchers, and clinicians who possess the necessary expertise in molecular biology, pharmacology, and clinical development.
Our Network
Relationships matter. We have built a robust network of relationships with Universities, labs, government, and institutional partners that span 3 continents.
We view the world as dynamic with cross border innovation in the United States, Middle East and Africa. This poses a unique opportunity for investors to invest in innovative companies in new markets.
These new markets possess growing demand, government initiatives, strategic locations, economic diversification, research and academic institutions, funding and resources.
The Middle East is transforming from an oil-driven to a data-driven economy, and Infusion 51a has joined the collective goal of strengthening their position as a global hub for the Fourth Industrial Revolution.
The UAE already has an impressive track record with healthcare investments, having attracted world-class institutions such as the Cleveland Clinic and education programs by NYU, and positioning Dubai among the top 10 best global destinations for medical tourism (Medical Tourism Index, 2021).
Our vision is to participate in this revolution by providing expertise and bridging USA’s technologies to this region, bringing both countries closer in sharing knowledge, data, and healthcare innovation.
This poses a unique opportunity for investors to be part of an innovative international project under convenient free zone rules and flexible regulations.
The world we want to create
Why we're different
Get your Easy Investors Guide
Get your Easy Investors Guide
Frequently Asked Questions
We have an in-depth due diligence system that helps us locate and target companies that meet our strict criteria: through data-driven financial analysis, we examine businesses and product viability, leadership quality, work ethic, and past track records.
In parallel, we conduct a deep dive into the companies’ ethos asking ourselves: who stays late? Who leaves early? Who values their employees? And who actually is committed to making long-term changes with their company?
We want to invest in honest, dedicated leaders with the drive and the integrity to reach their goals gallantly.
POTENTIAL HIGHER RETURNS for investors by increasing portfolio companies’ performance through operational acumen and standard process implementation
BETTER ACCESS to negotiated discounts from portfolio acquisitions leading to potentially higher exponential returns
REDUCED COST on operative and administrative tasks by implementing cost-effective solutions
As part of the investing world, it’s a given that large funds and seasoned investors should be great at maximizing your returns on investment. That sounds great, right? But all too often in our industry the mentality seems to be “make profit at whatever cost” often to the detriment of the business involved.
For example, most Wall Street funds are operating over $5B and are seasoned pros who actively seek out a weak business position and will push to take as much from a company as they can for as little as possible.
Therein lies the problem, these brokers often have little loyalty, and success is measured only by an ability to sell a deal over the likelihood of that investment actually delivering positive returns for investors.
Why you may ask? Because regardless of how those investments turn out, those on Wall Street will still get a percentage of the money raised and will still get paid.
Make no mistake: we are fierce negotiators and have a strong sense of accountability. We live for strategy briefs, detailed execution plans, and periodic reports that reveal if we’re on the right track or not.
Infusion 51a operates in a more holistic manner. We provide capital to organizations to enable them to hit milestones, build and implement operations and create value through successful leadership. We then bring in our broker team to capitalize the company at a higher yet fair valuation, which is how our investors make money.
We know actions speak louder than words, this is why we leave our impact-driven mark in every interaction.
From creating a work culture where selflessness, empathy and kindness is rewarded, to attending fundraising events, donating to nonprofit organizations and spreading the word on the importance of funding overlooked diseases, we are fully committed to living by our core values.
Our main impact-focused effort is a Facebook Support Group: “Together Against Glioblastoma”, which we created in partnership with Vivacitas Oncology, one of our Assets Under Management (AUM).
Over the group, we’re determined to share useful resources of the deadliest form of brain cancer, Glioblastoma Multiforme (GBM), for patients and relatives alike, to offer a safe space for venting and asking for support when it’s needed.
With the help of our engaged community, we’ve also developed successful media campaigns, such as #FacesNotNumbers, in which we’re starting to increase visibility on the human stories behind the predominantly devastating statistics of GBM.
Infusion 51a has built such strong, valuable relationships with our investors and the businesses we invest in, that we’re confident any of those would actively agree we’re motivated by a desire to improve our world, create positive change and deliver much-needed care to patients around the globe.
We have an in-depth due diligence system that helps us locate and target companies that meet our strict criteria: through data-driven financial analysis, we examine businesses and product viability, leadership quality, work ethic, and past track records.
In parallel, we conduct a deep dive into the companies’ ethos asking ourselves: who stays late? Who leaves early? Who values their employees? And who actually is committed to making long-term changes with their company?
We want to invest in honest, dedicated leaders with the drive and the integrity to reach their goals gallantly.
POTENTIAL HIGHER RETURNS for investors by increasing portfolio companies’ performance through operational acumen and standard process implementation
BETTER ACCESS to negotiated discounts from portfolio acquisitions leading to potentially higher exponential returns
REDUCED COST on operative and administrative tasks by implementing cost-effective solutions
As part of the investing world, it’s a given that large funds and seasoned investors should be great at maximizing your returns on investment. That sounds great, right? But all too often in our industry the mentality seems to be “make profit at whatever cost” often to the detriment of the business involved.
For example, most Wall Street funds are operating over $5B and are seasoned pros who actively seek out a weak business position and will push to take as much from a company as they can for as little as possible.
Therein lies the problem, these brokers often have little loyalty, and success is measured only by an ability to sell a deal over the likelihood of that investment actually delivering positive returns for investors.
Why you may ask? Because regardless of how those investments turn out, those on Wall Street will still get a percentage of the money raised and will still get paid.
Make no mistake: we are fierce negotiators and have a strong sense of accountability. We live for strategy briefs, detailed execution plans, and periodic reports that reveal if we’re on the right track or not.
Infusion 51a operates in a more holistic manner. We provide capital to organizations to enable them to hit milestones, build and implement operations and create value through successful leadership. We then bring in our broker team to capitalize the company at a higher yet fair valuation, which is how our investors make money.
We know actions speak louder than words, this is why we leave our impact-driven mark in every interaction.
From creating a work culture where selflessness, empathy and kindness is rewarded, to attending fundraising events, donating to nonprofit organizations and spreading the word on the importance of funding overlooked diseases, we are fully committed to living by our core values.
Our main impact-focused effort is a Facebook Support Group: “Together Against Glioblastoma”, which we created in partnership with Vivacitas Oncology, one of our Assets Under Management (AUM).
Over the group, we’re determined to share useful resources of the deadliest form of brain cancer, Glioblastoma Multiforme (GBM), for patients and relatives alike, to offer a safe space for venting and asking for support when it’s needed.
With the help of our engaged community, we’ve also developed successful media campaigns, such as #FacesNotNumbers, in which we’re starting to increase visibility on the human stories behind the predominantly devastating statistics of GBM.
Infusion 51a has built such strong, valuable relationships with our investors and the businesses we invest in, that we’re confident any of those would actively agree we’re motivated by a desire to improve our world, create positive change and deliver much-needed care to patients around the globe.
Technical investment questions
A fund is a collective investment institution constituted by fund managers (General Partners) and investors (limited partners). Fund operators wisely manage the capital of their partners and present them with broader investment opportunities, greater management expertise, and investment fees discounts than individual investors would hardly be able to obtain on their own.
Limited Partners have no operational responsibilities and are solely responsible for putting their money in and expecting the returns.
In essence, people investing in a fund like ours become part owners of the fund and, therefore, own equity in the business.
If an investor puts $1M into a $20M fund, the fund will now have $21M and the investor would have their proportionate equity. If the fund’s value grows to $42M then that investor’s equity would go to $2M. If the fund were to go down to $10.5M, that investor’s equity would be worth $500K.
The role of General Partners in a fund is to ensure their investors’ money is put to good use, locating it smartly according to their previous experiences and their market knowledge, in order to maximize the possibilities of increasing profits for investors.
Fund operations are paid for by taking a yearly 2% management fee of the overall value of the fund. This is broken down quarterly, resulting in 0.5% per quarter.
At Infusion 51a, we are taking 2% on approximately $10M, which is roughly $200,000 a year to operate the entire fund.
GPs also receive 20% of the growth of the fund’s value. For example: let’s say a fund grows from $20M to $100M, which equals $80M in profit. The investors would receive 80% of the profit ($64M) and the GPs would receive 20% ($16M).
By law, we are only allowed 100 accredited investors.
An accredited investor is an individual or a business entity that is allowed to trade securities that may not be registered with financial authorities.
To qualify as an accredited investor, you must:
- Have $1M net worth outside of your home, or
- Have made $200K (if single) a year for the past 2 consecutive years, or $300K (if married) combined with your spouse’s income —besides reasonably expecting the same income level in the current year.
An institution is an organization that is in the business of investing or has dedicated divisions to invest. An example would be the Navy’s Endowment Department, a financial institution, other funds, banks, Registered Advisors, Financial Advisors, etc.
On the other hand, a retail investor is a regular citizen who, regardless of their source of income, decides to grow their money by investing in stocks, real estate, or bonds. The higher retail investors’ net worth, the more sophisticated they are and the more likely it is that they have advisors that help them make decisions. There are also Ultra High Net Worth Individuals (UHNWIs) who have built massive amounts of wealth, although they are still “just” retail investors.
As a recent investment fund, it’s normal for investors to look for our background in the industry and for any hard proof that their money won’t go to waste.
However, the unpredictability of the market and the fast-shifting biotech industry is something not even big firms can escape from.
Just like with any other fund, there are higher risks in opportunities with higher potential for better returns.
We cannot foresee the results any of our operations will get, but we can promise we’ll look out for our investors’ best interests every damn chance we have.
A fund is a collective investment institution constituted by fund managers (General Partners) and investors (limited partners). Fund operators wisely manage the capital of their partners and present them with broader investment opportunities, greater management expertise, and investment fees discounts than individual investors would hardly be able to obtain on their own.
Limited Partners have no operational responsibilities and are solely responsible for putting their money in and expecting the returns.
In essence, people investing in a fund like ours become part owners of the fund and, therefore, own equity in the business.
If an investor puts $1M into a $20M fund, the fund will now have $21M and the investor would have their proportionate equity. If the fund’s value grows to $42M then that investor’s equity would go to $2M. If the fund were to go down to $10.5M, that investor’s equity would be worth $500K.
The role of General Partners in a fund is to ensure their investors’ money is put to good use, locating it smartly according to their previous experiences and their market knowledge, in order to maximize the possibilities of increasing profits for investors.
Fund operations are paid for by taking a yearly 2% management fee of the overall value of the fund. This is broken down quarterly, resulting in 0.5% per quarter.
At Infusion 51a, we are taking 2% on approximately $10M, which is roughly $200,000 a year to operate the entire fund.
GPs also receive 20% of the growth of the fund’s value. For example: let’s say a fund grows from $20M to $100M, which equals $80M in profit. The investors would receive 80% of the profit ($64M) and the GPs would receive 20% ($16M).
By law, we are only allowed 100 accredited investors.
An accredited investor is an individual or a business entity that is allowed to trade securities that may not be registered with financial authorities.
To qualify as an accredited investor, you must:
- Have $1M net worth outside of your home, or
- Have made $200K (if single) a year for the past 2 consecutive years, or $300K (if married) combined with your spouse’s income —besides reasonably expecting the same income level in the current year.
An institution is an organization that is in the business of investing or has dedicated divisions to invest. An example would be the Navy’s Endowment Department, a financial institution, other funds, banks, Registered Advisors, Financial Advisors, etc.
On the other hand, a retail investor is a regular citizen who, regardless of their source of income, decides to grow their money by investing in stocks, real estate, or bonds. The higher retail investors’ net worth, the more sophisticated they are and the more likely it is that they have advisors that help them make decisions. There are also Ultra High Net Worth Individuals (UHNWIs) who have built massive amounts of wealth, although they are still “just” retail investors.
As a recent investment fund, it’s normal for investors to look for our background in the industry and for any hard proof that their money won’t go to waste.
However, the unpredictability of the market and the fast-shifting biotech industry is something not even big firms can escape from.
Just like with any other fund, there are higher risks in opportunities with higher potential for better returns.
We cannot foresee the results any of our operations will get, but we can promise we’ll look out for our investors’ best interests every damn chance we have.